Skip to main content
Glenmark Pharmaceuticals ltd logo

Glenmark Pharmaceuticals ltd — Investor Relations & Filings

Ticker · GLENMARK ISIN · INE935A01035 LEI · 335800WKECZXIIT9GK20 BSE.NS Manufacturing
Open in API
Filings indexed 1,034 across all filing types
Latest filing 2024-01-31 Regulatory Filings
Country IN India
Listing BSE.NS GLENMARK

About Glenmark Pharmaceuticals ltd

https://glenmarkpharma.com/

Glenmark Pharmaceuticals Ltd. is a research-driven global organization focused on the development, manufacturing, and marketing of generic, specialty, and over-the-counter medicines. The company maintains a specialized focus on therapeutic areas including dermatology, respiratory health, and oncology. It operates a robust research and development pipeline featuring New Chemical Entities (NCEs) and New Biological Entities (NBEs), supported by multiple global R&D centers. Its commercial footprint extends across North America, Europe, and emerging markets. The company is distinguished by its expertise in complex generics and its integrated approach to drug discovery and formulation development. Glenmark utilizes a network of advanced manufacturing facilities to deliver high-quality healthcare solutions globally, emphasizing innovation and accessibility in its product portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a partnership between Glenmark Pharmaceuticals and Pfizer to launch a new drug, Abrocitinib, in India. It includes marketing authorization details, product information, and quotes from company executives. There are no financial statements, regulatory filings, voting results, or management discussions. The document is a corporate announcement about a product launch and partnership, not a financial report, regulatory filing, or meeting material. Therefore, it fits best under the category of a general regulatory announcement or corporate news update, which corresponds to Regulatory Filings (RNS). The document length is 9476 characters, which is substantial but the content is clearly a press release rather than a financial or governance report.
2024-01-31 English
Board Meeting — GLENMARK PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 14-Feb-2024 to inter-alia consider and approve the Unaudited Financial results of the Comp…
Regulatory Filings
2024-01-30 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing about an upcoming Board Meeting scheduled for February 14, 2024, to consider and approve the unaudited financial results for the third quarter and nine months ended December 31, 2023. It references regulatory compliance under SEBI regulations and mentions the closure of the trading window for insider trading prevention. The document does not contain any financial data or detailed results but is an announcement of a future event related to financial reporting. The document length is only 2012 characters, which is short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Interim Report or Earnings Release.
2024-01-30 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges notifying about an upcoming Board Meeting scheduled for February 14, 2024. The purpose of the meeting is to consider and approve the unaudited financial results for the third quarter and nine months ended December 31, 2023. It also mentions the closure of the trading window for insiders in compliance with insider trading regulations. The document does not contain the financial results themselves but is an announcement of the meeting where these results will be approved. The document length is short (2012 characters) and it serves as a notification rather than the actual financial report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement about an upcoming board meeting and financial results approval, not the financial report itself or a detailed management discussion.
2024-01-30 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing a new alliance between Glenmark Pharmaceuticals and Ichnos Sciences to accelerate innovation in cancer treatment. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed financial or governance reports. The content is a corporate announcement about a strategic collaboration and pipeline overview, typical of a press release or media release. It is not an Annual Report, Interim Report, Earnings Release, or any other formal regulatory filing. The document is about a business development and innovation alliance, which does not fit into categories like M&A, Capital Update, or Legal Proceedings. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-01-30 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the signing of a license agreement between Glenmark Pharmaceuticals and other biopharmaceutical companies for the drug KN035 (Envafolimab). It details the terms of the agreement, the drug's background, and company information. There are no financial statements, regulatory certifications, voting results, or management changes. The document is a corporate announcement about a licensing deal, which fits best under Capital/Financing Update (CAP) as it relates to a significant business transaction involving licensing and commercialization rights. The document length is over 12,000 characters and contains substantive information about the agreement, not just a brief notice or report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2024-01-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.